Clinical Trials Using Ibrutinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ibrutinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 75

  • Vascular Disrupting Agent BNC105P and Ibrutinib in treating Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia

    This phase I trial studies the side effects and best dose of vascular disrupting agent BNC105P when given with ibrutinib in treating participants with chronic lymphocytic leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as vascular disrupting agent BNC105P, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vascular disrupting agent BNC105P with ibrutinib may work better in treating participants with chronic lymphocytic leukemia.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

  • Daratumumab and Ibrutinib in Treating Patients with Symptomatic Chronic Lymphocytic Leukemia

    This phase Ib trials studies the side effects of daratumumab and ibrutinib and how well they work in treating patients with symptomatic chronic lymphocytic leukemia. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving daratumumab and ibrutinib may work better in treating patients with chronic lymphocytic leukemia.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

    This phase I trial studies the side effects and best dose of avelumab, utomilumab, rituximab, ibrutinib, and combination chemotherapy in treating patients with diffuse large B-cell lymphoma or mantle cell lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as avelumab, utomilumab, and rituximab, may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as etoposide phosphate, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab, utomilumab, rituximab, ibrutinib, and combination chemotherapy may work better in treating patients with diffuse large B-cell lymphoma or mantle cell lymphoma.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Venetoclax and Ibrutinib in Treating Patients with Progressive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase I trial studies the best dose of venetoclax and ibrutinib when given together in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that is growing, has spread to other places in the body, or is getting worse. Venetoclax and ibrutinib may stop the growth the cancer cells by blocking some of the enzymes needed for cell growth.
    Location: University of California San Diego, San Diego, California

  • Ibrutinib and Lenalidomide in Treating Patients with Myelodysplastic Syndrome

    This phase I trial studies the side effects and best dose of ibrutinib when giving together with lenalidomide in treating patients with myelodysplastic syndrome. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and lenalidomide may work better in treating patients with myelodysplastic syndrome.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Ibrutinib in Treating Participants with Untreated High Risk Smoldering Mantle Cell Lymphoma

    This phase II trial studies how well ibrutinib works in treating participants with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ibrutinib in Treating Acute Leukemia in Patients after Reduced-Intensity Conditioning and Stem Cell Transplant

    This phase II trial studies how well ibrutinib works in treating acute leukemia in patients after reduced-intensity conditioning and stem cell transplant. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed / Refractory B-cell Lymphoma

    Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved after treatment Design: Participants will be screened with: - Medical history - Physical exam - Blood, urine, and heart tests - Tissue sample from previous procedure - Imaging scans - Registration for counseling on the risks of lenalidomide. They must get counseling at least every 28 days. Participants will have a bone marrow aspiration before treatment. Participants may have tumor samples taken. Participants will get ViPOR in 21-day cycles. For up to 6 cycles: - Participants will get one drug by IV on days 1 and 2. - Participants will take the other four drugs by mouth on most days. After their first dose of venetoclax, they will stay in the clinic for at least 8 hours and return the next day for monitoring. They may be admitted for more drugs or monitoring. Participants will keep a drug diary. Participants will have a physical exam and blood and urine tests at least once per cycle. They will have scans 4 times over 6 cycles. Participants will have a visit about 1 month after their last dose of study drug. They will then have visits every few months for 3 years, and once a year for years 4 and 5. Visits include a physical exam, blood tests, and scans.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Patient-Derived Xenografts in Personalizing Treatment for Patients with Relapsed / Refractory Mantle Cell Lymphoma

    This early phase I pilot trial studies how well patient-derived xenografts work in personalizing treatment for patients with mantle cell lymphoma that has come back (relapsed) or that isn't responding to treatment (refractory). Xenograft models involve taking a piece of tissue from a tumor that was previously collected and putting that tissue inside of a mouse in the laboratory. This allows the tumor to grow in the mouse so that researchers can test the effects of certain drugs. If the drugs have an effect on the tumor(s) in the mice, patients may receive that treatment for mantle cell lymphoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ibrutinib in Treating Participants with Early Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well ibrutinib works in treating participants with early stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients with Indolent Non-Hodgkin's Lymphomas

    This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Ibrutinib and Pembrolizumab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma

    This phase I / IIa trial studies the side effects of ibrutinib and pembrolizumab and how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib and pembrolizumab may work better in treating patients with mantle cell lymphoma.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Pembrolizumab and Ibrutinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery

    This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with melanoma.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients with Relapsed or Refractory Grade 1-3A Follicular Lymphoma

    This phase Ib / II trial studies the side effects and best dose of toll-like receptor 9 (TLR9) agonist SD-101 when given together with ibrutinib and radiation therapy and to see how well they work in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement or no longer responds to treatment. Immunostimulants such as TLR9 agonist SD-101 may increase the ability of the immune system to fight infection and disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving TLR9 agonist SD-101 with ibrutinib and radiation therapy may induce an immune response and prolong anti-tumor response.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Obinutuzumab in Combination with Ibrutinib in Treating Patients with Relapsed Mantle Cell Lymphoma

    This phase II trial studies how well obinutuzumab works in combination with ibrutinib in treating patients with mantle cell lymphoma that has returned (relapsed) or that does not respond to treatment (refractory). Obinutuzumab binds to a protein called cluster of differentiation (CD)20, which is found on B cells and some types of leukemia and lymphoma cells and help the immune system kill cancer cells. Ibrutinib blocks a protein called Bruton’s tyrosine kinase (BTK), which may help keep cancer cells from growing. Giving obinutuzumab in combination with ibrutinib may kill more cancer cells.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Ibrutinib in Treating Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia after Front-Line Therapy

    This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who responded to initial treatment used to reduce a cancer (front-line therapy) but have residual disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Mayo Clinic in Florida, Jacksonville, Florida

  • Ibrutinib Given before Surgery in Treating Patients with Prostate Cancer

    This phase II trial studies the side effects of ibrutinib and to see how well it works when given before surgery, in treating patients with prostate cancer. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia

    This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab together may work better in treating chronic lymphocytic leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

    Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
    Location: 9 locations

  • A Long-term Extension Study of PCI-32765 (Ibrutinib)

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for participants who are currently enrolled in PCI-32765 studies that have been completed according to the parent protocol, are actively receiving treatment with PCI-32765, and who continue to benefit from PCI-32765 treatment.
    Location: 4 locations

  • Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

    This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

    This phase Ib / II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Pevonedistat and Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back (relapsed) or has stopped responding to other treatments (refractory). Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients with Multiple Myeloma Ineligible for Transplant

    This phase I / II trial studies the best dose and side effects of ibrutinib when given together with lenalidomide and dexamethasone and how well they work in treating patients with multiple myeloma that are not eligible for transplant. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.
    Location: Mayo Clinic in Florida, Jacksonville, Florida

  • Selinexor and Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of selinexor when given together with ibrutinib in treating patients with chronic lymphocytic leukemia or aggressive non-Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment. Selinexor and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations